Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III) (RENASCENT III)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02900937
Recruitment Status : Recruiting
First Posted : September 15, 2016
Last Update Posted : November 25, 2016
Information provided by (Responsible Party):
Amaranth Medical Inc.

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 2018
  Estimated Study Completion Date : June 2022
Granada JF. The Amaranth PLLA based bioresorbable scaffold (ABRS): Experimental and early human results. TCT presentation 2013.
Granada JF. BRS with clinical data III, Amaranth: Differentiating features and clinical update. TCT presentation 2014.
Colombo A, for the FORTITUDE Study Investigators. 1-Year Clinical and Imaging Outcomes of a Novel Ultra High Molecular Weight PLLA Sirolimus-Eluting Coronary BRS: A Prospective Multicenter International Investigation (The FORTITUDE® Study). TCT presentation 2016.
Granada JF. From Aptitude to Magnitude: Progress Towards the Development of a Thin-Walled Novel PLLA Based Bioresorbable Scaffold. TCT presentation 2016.